Skip to main content
Biosynex logo

Biosynex — Investor Relations & Filings

Ticker · ALBIO ISIN · FR0011005933 LEI · 969500H4BGE1HBLGP566 PA Manufacturing
Open in API
Filings indexed 198 across all filing types
Latest filing 2025-06-17 Regulatory Filings
Country FR France
Listing PA ALBIO

About Biosynex

https://www.biosynex.com/en/

Biosynex is a company that specializes in the design, manufacture, and distribution of medical diagnostic solutions. Its core product line consists of Rapid Diagnostic Tests (RDTs) for both professional use in clinical settings and for self-testing by the general public. The professional portfolio includes point-of-care (POC) instruments, molecular biology diagnostics (such as PCR tests), and a wide array of immunodiagnostic assays. For the consumer market, Biosynex offers various self-tests and a range of prevention and monitoring devices, including thermometers, blood pressure monitors, and pulse oximeters. The company focuses on providing simple, rapid, and effective tools for screening, diagnosis, and prevention.

Recent filings

Filing Released Lang Actions
BIOSYNEX SA: LA FOOD AND DRUG ADMINSITRATION ATTRIBUE LE STATUT “BREAKTHROUGH DEVICE” (INNOVATION DE RUPTURE) A L’AUTOTEST DE DIAGNOSTIC DU VIH SURE CHECK®
Regulatory Filings Classification · 100% confidence The document is a press release dated June 17, 2025, announcing that the US FDA granted 'Breakthrough Device' status to Chembio's SURE CHECK® HIV self-test. It details the significance of this regulatory milestone and includes quotes from management. Crucially, it also contains a section titled 'Prochaine communication' which explicitly announces the date for the 'Chiffre d'affaires 2ème trimestre 2025' (Q2 2025 Revenue). This structure—a significant operational/regulatory update combined with an announcement of a future financial report release—is characteristic of an Earnings Release (ER) or a general press release that includes forward-looking operational news. Since the core content is a major regulatory achievement (not financial results themselves) and it announces a future earnings date, it functions primarily as an announcement of significant, non-financial corporate news, often bundled with or preceding an ER. However, given the options, this is a general corporate announcement about a regulatory event and future financial reporting schedule. It is not a full financial report (10-K, IR), a transcript (CT), or a specific shareholder/director filing. It most closely resembles an Earnings Release (ER) because it announces the date of the next earnings release, even though the main body is regulatory news. If the document were purely regulatory news without the earnings announcement, 'RNS' might apply, but the inclusion of the future earnings date strongly suggests an ER context or a related corporate update.
2025-06-17 French
BIOSYNEX SA: LA FOOD AND DRUG ADMINSITRATION ATTRIBUE LE STATUT BREAKTHROUGH DEVICE (INNOVATION DE RUPTURE) A LAUTOTEST DE DIAGNOSTIC DU VIH SURE CHECK
Regulatory Filings Classification · 100% confidence The document is titled 'News Details' and is explicitly labeled as 'Information réglementaire' (Regulatory Information) transmitted by EQS Group. It announces a specific event: the US FDA granting 'Breakthrough Device' status to a product (HIV self-test). The document structure, including contact information, company boilerplate, and the mention of 'Catégorie AMF : Informations privilégiées / Autres communiqués' (AMF Category: Inside Information / Other announcements), strongly suggests this is a press release or regulatory disclosure of material, non-financial news. Since it is not a full financial report (10-K, IR), an earnings release (ER), or a transcript (CT), and it is a specific regulatory announcement, the most appropriate general category for non-standard, material regulatory news that doesn't fit elsewhere is 'Regulatory Filings' (RNS), as it serves as a general disclosure mechanism for such events, especially when the content is not a specific financial filing type listed.
2025-06-17 French
BIOSYNEX SA: RESULTATS ANNUELS 2024 - ACCELERATION DE LA REORGANISATION DU GROUPE EN 2025
Earnings Release Classification · 99% confidence The document is titled "RESULTATS ANNUELS 2024" (Annual Results 2024) and presents a detailed summary of the company's financial performance for the fiscal year ended December 31, 2024. It includes key performance indicators (Revenue, Gross Margin, Operating Result, Net Result), a comparative table of consolidated figures for 2024 FY vs 2023 FY, management commentary on the results, and outlook for 2025. Although it mentions that the accounts will be submitted to the next general meeting and that audit procedures are ongoing, the core content is the comprehensive annual financial disclosure. This aligns best with the definition of an Annual Report (10-K), which covers full financial performance. Since the text is extensive (over 13,000 characters) and contains the full results, it is classified as the report itself, not just a publication announcement (RPA). The French context suggests this is the equivalent of a 10-K filing, even if the specific SEC form name isn't present. FY 2024
2025-04-23 French
BIOSYNEX SA: RESULTATS ANNUELS 2024 - ACCELERATION DE LA REORGANISATION DU GROUPE EN 2025
Earnings Release Classification · 100% confidence The document is titled "BIOSYNEX SA: RESULTATS ANNUELS 2024" (Annual Results 2024) and contains detailed consolidated financial figures for the fiscal year ended December 31, 2024, including revenue, gross margin, operating result, and net result. It explicitly mentions that the accounts were approved by the Board on April 22, 2025, and will be submitted to the next shareholders' meeting. This content strongly indicates a comprehensive annual financial disclosure. Although it is presented as a press release ('Communiqué de presse') and mentions 'Information réglementaire', the substance is the full annual financial performance review, which aligns best with the Annual Report category (10-K), even if the specific filing format might be a local equivalent or an Earnings Release (ER) that contains the full annual data. Given the depth of the financial tables and the reference to 'RESULTATS ANNUELS 2024', it is more substantial than a typical ER. However, since the document states the audit procedures are ongoing ('Les procédures d’audit des comptes 2024 sont en cours') and it is a press release announcing the results that will be submitted to the AGM, it functions as the primary release of the annual figures. In many jurisdictions, the formal 'Annual Report' (10-K equivalent) is filed later. Since this document provides the full annual results summary and tables, it is classified as the primary release of annual results. If the document were significantly shorter and only pointed to the attached report, it would be RPA. Since it contains the data itself, it is closest to the comprehensive annual disclosure. Given the options, '10-K' is for the official yearly report, and 'ER' is for periodical results. Since this covers the full year, '10-K' is the most appropriate fit for the content type, representing the annual financial disclosure, even if it's a preliminary release. FY 2024
2025-04-23 French
Franchissement de seuil
Major Shareholding Notification Classification · 99% confidence The document is titled "Déclaration de franchissement de seuil (article L. 233-7 du code de commerce)" and details a change in the percentage of voting rights held by a concert group (ALA Financière, M. Larry Abensur, and Mme Anita Abensur) in BIOSYNEX, crossing the 50% threshold. This type of filing specifically reports changes in significant share ownership or control thresholds, which aligns directly with the definition of Major Shareholding Notification (MRQ). Although it mentions a capital increase, the primary purpose and structure of the document are to declare the crossing of a threshold by existing shareholders/concert parties.
2025-03-06 French
BIOSYNEX SA: DECLARATION DU NOMBRE DACTIONS ET DES DROITS DE VOTE AU 28 FEVRIER 2025
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled "BIOSYNEX SA: DECLARATION DU NOMBRE D’ACTIONS ET DES DROITS DE VOTE AU 28 FEVRIER 2025" (Declaration of the number of shares and voting rights as of February 28, 2025). It explicitly states it is providing the total number of shares and voting rights as required by French commercial code and AMF regulations. This type of mandatory disclosure regarding the capital structure and voting power, especially when presented as a brief regulatory update, aligns best with the category for Declaration of Voting Results & Voting Rights Announcements (DVA), as it declares the total voting rights count. Although it is a regulatory filing, DVA is more specific than the general RNS fallback. The document is short and presents definitive figures rather than announcing a larger report, thus avoiding the RPA classification.
2025-03-05 French

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.